Trials / Completed
CompletedNCT02980692
Efficacy and Safety Study of SUNPG1623
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 391 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SUNPG1623 I | injection |
| DRUG | SUNPG1623 II | injection |
| DRUG | SUNPG1623 III | injection |
| DRUG | SUNPG1623 IV | injection |
| DRUG | PLACEBO | injection |
Timeline
- Start date
- 2017-04-19
- Primary completion
- 2019-03-01
- Completion
- 2019-09-24
- First posted
- 2016-12-02
- Last updated
- 2023-01-27
- Results posted
- 2021-05-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02980692. Inclusion in this directory is not an endorsement.